Literature DB >> 35802246

miR-34b-3p Inhibition of eIF4E Causes Post-stroke Depression in Adult Mice.

Xiao Ke1,2, Manfei Deng1,2, Zhuoze Wu3, Hongyan Yu1,2, Dian Yu1,2, Hao Li1,2, Youming Lu2,4, Kai Shu5, Lei Pei6,7.   

Abstract

Post-stroke depression (PSD) is a serious and common complication of stroke, which seriously affects the rehabilitation of stroke patients. To date, the pathogenesis of PSD is unclear and effective treatments remain unavailable. Here, we established a mouse model of PSD through photothrombosis-induced focal ischemia. By using a combination of brain imaging, transcriptome sequencing, and bioinformatics analysis, we found that the hippocampus of PSD mice had a significantly lower metabolic level than other brain regions. RNA sequencing revealed a significant reduction of miR34b-3p, which was expressed in hippocampal neurons and inhibited the translation of eukaryotic translation initiation factor 4E (eIF4E). Furthermore, silencing eIF4E inactivated microglia, inhibited neuroinflammation, and abolished the depression-like behaviors in PSD mice. Together, our data demonstrated that insufficient miR34b-3p after stroke cannot inhibit eIF4E translation, which causes PSD by the activation of microglia in the hippocampus. Therefore, miR34b-3p and eIF4E may serve as potential therapeutic targets for the treatment of PSD.
© 2022. Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences.

Entities:  

Keywords:  Hippocampus; Microglia; Neuroinflammation; Post-stroke depression; miRNA

Year:  2022        PMID: 35802246     DOI: 10.1007/s12264-022-00898-7

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  64 in total

1.  Post-Stroke Depression in Jordan: Prevalence Correlates and Predictors.

Authors:  Shahnaz Mohammed Ayasrah; Muayyad M Ahmad; Iman Amin Basheti
Journal:  J Stroke Cerebrovasc Dis       Date:  2017-12-27       Impact factor: 2.136

Review 2.  Post-Stroke Depression: A Review.

Authors:  Robert G Robinson; Ricardo E Jorge
Journal:  Am J Psychiatry       Date:  2015-12-18       Impact factor: 18.112

3.  Depression after stroke: a prospective epidemiological study.

Authors:  Ellen M Whyte; Benoit H Mulsant; Joni Vanderbilt; Hiroko H Dodge; Mary Ganguli
Journal:  J Am Geriatr Soc       Date:  2004-05       Impact factor: 5.562

4.  The Correlation between Depression, Balance, and Physical Functioning Post Stroke.

Authors:  Alia A Alghwiri
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-11-23       Impact factor: 2.136

Review 5.  Poststroke depression: a review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery.

Authors:  Murray Flaster; Aparna Sharma; Murali Rao
Journal:  Top Stroke Rehabil       Date:  2013 Mar-Apr       Impact factor: 2.119

6.  Major depression in stroke patients. A 3-year longitudinal study.

Authors:  M Aström; R Adolfsson; K Asplund
Journal:  Stroke       Date:  1993-07       Impact factor: 7.914

7.  Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression.

Authors:  David G S Perahia; Deborah Quail; Durisala Desaiah; Angel L Montejo; Alan F Schatzberg
Journal:  J Psychiatr Res       Date:  2008-08-15       Impact factor: 4.791

Review 8.  The neurobiology of depression and antidepressant action.

Authors:  Paul Willner; Jørgen Scheel-Krüger; Catherine Belzung
Journal:  Neurosci Biobehav Rev       Date:  2012-12-19       Impact factor: 8.989

Review 9.  Post stroke depression: epidemiology, pathophysiology, and biological treatment.

Authors:  Ellen M Whyte; Benoit H Mulsant
Journal:  Biol Psychiatry       Date:  2002-08-01       Impact factor: 13.382

10.  Post-stroke depression, anxiety, and stress symptoms and their associated factors: A cross-sectional study.

Authors:  Khader A Almhdawi; Alza Alazrai; Saddam Kanaan; Awni A Shyyab; Alaa O Oteir; Zaid Modhi Mansour; Hanan Jaber
Journal:  Neuropsychol Rehabil       Date:  2020-05-18       Impact factor: 2.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.